MetLife Investment Management’s Avadel Pharmaceuticals AVDL Stock Holding History

MetLife Investment Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,708	Closed	-$1.09M	–	2772
2025 Q4	$1.09M	Sell	50,708 -5,253	-9%	-$102K	0.01%	1377
2025 Q3	$855K	Hold	55,961	–	–	﹤0.01%	1540
2025 Q2	$495K	Hold	55,961	–	–	﹤0.01%	1679
2025 Q1	$438K	Sell	55,961 -1,107	-2%	-$9.27K	﹤0.01%	1790
2024 Q4	$600K	Buy	57,068 +3,271	+6%	+$39.7K	﹤0.01%	1704
2024 Q3	$706K	Buy	53,797 +30,313	+129%	+$462K	﹤0.01%	1593
2024 Q2	$330K	Buy	+23,484	New	+$383K	﹤0.01%	1951

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

MetLife Investment Management's AVDL Position: Q1 2026 in Review

MetLife Investment Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 50,708 shares — an estimated $1.09M sold.

MetLife Investment Management first reported a position in AVDL in Q2 2024 and held it in 7 quarters. The position peaked at $1.09M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

MetLife Investment Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
MetLife Investment Management sold 50,708 Avadel Pharmaceuticals shares in Q1 2026, an estimated $1.09M.
MetLife Investment Management first reported a position in Avadel Pharmaceuticals in Q2 2024 and held it in 7 quarters.
MetLife Investment Management's Avadel Pharmaceuticals position peaked at $1.09M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.